Jong-Gyun Kim

Jong-Gyun Kim is a notable inventor based in Anyang-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have potential applications in cancer treatment. With a total of 2 patents to his name, his work reflects a commitment to advancing medical science.

Latest Patents

One of his latest patents is focused on a quinazoline derivative or its salt, along with a pharmaceutical composition comprising the same. This invention provides a quinazoline derivative that exhibits selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit. This characteristic makes it a promising candidate for preventing or treating cancer while minimizing side effects such as lymphopenia-associated inflammatory responses.

Another significant patent involves a benzo[d]thiazole derivative or its salt, along with a pharmaceutical composition that includes the same. This invention selectively inhibits the protein-protein interaction between KRS and a laminin receptor, effectively inhibiting the migration of cancer cells. As a result, this benzo[d]thiazole derivative may be beneficial in preventing or treating diseases associated with cancer cell metastasis.

Career Highlights

Jong-Gyun Kim is currently associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on innovative research and development in the pharmaceutical sector.

Collaborations

He has collaborated with notable colleagues such as Eui-Chul Lee and Jin-Hwi Park, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Jong-Gyun Kim's contributions to the field of pharmaceuticals, particularly through his innovative patents, highlight his role as a key inventor in cancer treatment research. His work continues to pave the way for advancements in medical science.

Profile summary based on public USPTO records.